fluorescein-5-isothiocyanate has been researched along with tamoxifen in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ariens, AT; Labruyère, W; Lindeman, J; van Marle, J; van Weeren-Kramer, J | 1 |
| Ogawa, Y; Onishi, S; Saibara, T | 1 |
| Bae, SW; Jeong, JK; Jo, I; Kim, HP; Lee, HK; Lee, JY | 1 |
| Hiramoto, K; Inoue, M; Sato, EF; Tanaka, H; Yanagihara, N | 1 |
| Alonso, R; Diaz, M; Gonzalez, M; Marin, R; Morales, A | 1 |
| Badgeley, MA; Bagalkot, V; Deiuliis, JA; Kampfrath, T; Maiseyeu, A; Rajagopalan, S | 1 |
| Nankali, E; Shaabanzadeh, M; Torbati, MB | 1 |
7 other study(ies) available for fluorescein-5-isothiocyanate and tamoxifen
| Article | Year |
|---|---|
Estrogen receptors in human breast cancer. I. Specificity of the histochemical localization of estrogen receptors using an estrogen-albumin FITC complex.
Topics: Animals; Breast Neoplasms; Cattle; Cell Transformation, Neoplastic; Estrogens; Fluorescein-5-isothiocyanate; Fluoresceins; Frozen Sections; Histocytochemistry; Humans; Nafoxidine; Receptors, Estrogen; Serum Albumin, Bovine; Tamoxifen; Thiocyanates; Time Factors | 1982 |
Tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Biomarkers; Breast Neoplasms; CD36 Antigens; Estrogen Antagonists; Fatty Liver; Female; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Tamoxifen | 1998 |
Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae.
Topics: Animals; Calcium; Cattle; Cell Membrane; Cells, Cultured; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fluorescein-5-isothiocyanate; Fulvestrant; Humans; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Receptors, Estrogen; Serum Albumin, Bovine; Tamoxifen | 1999 |
Effect of 17beta-estradiol on immunosuppression induced by ultraviolet B irradiation.
Topics: Animals; Dermatitis, Contact; Estradiol; Estrogen Antagonists; Female; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Immune Tolerance; Interleukin-10; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Skin; Specific Pathogen-Free Organisms; Tamoxifen; Ultraviolet Rays | 2004 |
Estrogen inhibition of norepinephrine responsiveness is initiated at the plasma membrane of GnRH-producing GT1-7 cells.
Topics: Cell Line, Tumor; Cell Membrane; Cyclic AMP; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Estrogens; Estrogens, Conjugated (USP); Fluorescein-5-isothiocyanate; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Hypothalamus; NAD; Neurons; Norepinephrine; Phenols; Protein Binding; Pyrazoles; Serum Albumin, Bovine; Tamoxifen | 2007 |
Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Cell Line; Cholesterol; Cytokines; Fluorescein-5-isothiocyanate; Gadolinium; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Nanoparticles; Obesity; Paclitaxel; Phagocytosis; Phosphatidylethanolamines; Phosphatidylserines; Phospholipases A2; Polyethylene Glycols; Polystyrenes; Rosiglitazone; Tamoxifen; Thiazolidinediones | 2015 |
Fluorescent tamoxifen-encapsulated nanocapsules functionalized with folic acid for enhanced drug delivery toward breast cancer cell line MCF-7 and cancer cell imaging.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Drug Stability; Female; Fluorescein-5-isothiocyanate; Folic Acid; Humans; Inhibitory Concentration 50; MCF-7 Cells; Nanocapsules; Solubility; Tamoxifen | 2020 |